PGNY logo

Progyny (PGNY) Company Overview

Profile

Full Name:

Progyny, Inc.

Sector:

Healthcare

Country:

United States

IPO:

October 25, 2019

Indexes:

Not included

Description:

Progyny, Inc. is an American company specializing in managing benefits in the field of reproductive health. Previously known as Auxogyn, Inc., the company changed its name to Progyny, Inc. in 2015. Progyny, Inc. was registered in 2008, with its headquarters located in New York, New York. The company offers the Smart Cycle treatment package, which includes all necessary diagnostic tests and access to the latest technologies (such as preimplantation genetic testing in the case of IVF treatment). Smart Cycle provides 17 different procedure packages that can be used independently or in combination, depending on the participant's needs. The company also offers Progyny Rx - a comprehensive pharmacy benefit solution that provides participants with access to medications needed during their treatment.

Key Details

Price

$21.91

Annual Revenue

$1.09 B(+38.34% YoY)

Annual EPS

$0.62(+106.67% YoY)

Beta

0.32

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 28, 25 JP Morgan
Neutral
Dec 2, 24 JP Morgan
Neutral
Nov 14, 24 Barclays
Overweight
Nov 13, 24 Truist Securities
Hold
Nov 13, 24 Canaccord Genuity
Hold
Nov 13, 24 B of A Securities
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight
Sep 20, 24 Canaccord Genuity
Hold
Sep 19, 24 Truist Securities
Buy
Sep 19, 24 Leerink Partners
Market Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
PGNY
zacks.comJanuary 29, 2025

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
PGNY
globenewswire.comJanuary 16, 2025

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
PGNY
seekingalpha.comDecember 30, 2024

Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy.

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY
prnewswire.comDecember 18, 2024

SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY
globenewswire.comDecember 11, 2024

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
PGNY
globenewswire.comDecember 3, 2024

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
PGNY
seekingalpha.comNovember 17, 2024

I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.

Why Progyny Stock Crashed Today
Why Progyny Stock Crashed Today
Why Progyny Stock Crashed Today
PGNY
fool.comNovember 13, 2024

Why Progyny Stock Crashed Today

Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
PGNY
seekingalpha.comNovember 12, 2024

Progyny, Inc (NASDAQ:PGNY ) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Allen Lutz - Bank of America Sarah James - Cantor Fitzgerald Michael Cherny - Leering Partners Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Stephanie Davis - Barclays Scott Schoenhaus - KeyBanc Richard Close - Canaccord Genuity David Larsen - BTIG Operator Good day, and welcome to the Progyny, Inc. Third Quarter Earnings Conference Call. At this time all participants have been placed on listen-only mode.

Progyny (PGNY) Tops Q3 Earnings Estimates
Progyny (PGNY) Tops Q3 Earnings Estimates
Progyny (PGNY) Tops Q3 Earnings Estimates
PGNY
zacks.comNovember 12, 2024

Progyny (PGNY) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.16 per share a year ago.

FAQ

  • What is the ticker symbol for Progyny?
  • Does Progyny pay dividends?
  • What sector is Progyny in?
  • What industry is Progyny in?
  • What country is Progyny based in?
  • When did Progyny go public?
  • Is Progyny in the S&P 500?
  • Is Progyny in the NASDAQ 100?
  • Is Progyny in the Dow Jones?
  • When was Progyny's last earnings report?
  • When does Progyny report earnings?
  • Should I buy Progyny stock now?

What is the ticker symbol for Progyny?

The ticker symbol for Progyny is NASDAQ:PGNY

Does Progyny pay dividends?

No, Progyny does not pay dividends

What sector is Progyny in?

Progyny is in the Healthcare sector

What industry is Progyny in?

Progyny is in the Health Information Services industry

What country is Progyny based in?

Progyny is headquartered in United States

When did Progyny go public?

Progyny's initial public offering (IPO) was on October 25, 2019

Is Progyny in the S&P 500?

No, Progyny is not included in the S&P 500 index

Is Progyny in the NASDAQ 100?

No, Progyny is not included in the NASDAQ 100 index

Is Progyny in the Dow Jones?

No, Progyny is not included in the Dow Jones index

When was Progyny's last earnings report?

Progyny's most recent earnings report was on Nov 12, 2024

When does Progyny report earnings?

The next expected earnings date for Progyny is Feb 27, 2025

Should I buy Progyny stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions